Emergent Partners with BC Health Authority to Expand NARCAN® Program
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 09 2026
0mins
Should l Buy EBS?
Source: Newsfilter
- Partnership Expansion: Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program, following an $18 million CAD investment by the B.C. government aimed at enhancing community access to naloxone and addressing the opioid crisis.
- Delivery Milestones: Since 2016, Emergent has delivered over 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., showcasing the company's robust capability in responding to public health threats and solidifying its leadership in life-saving products.
- Community Impact: The expansion will make NARCAN® Nasal Spray available in various communities, pharmacies, and public institutions across B.C., significantly enhancing public response capabilities to opioid overdoses and potentially reducing related mortality rates.
- Strategic Collaboration: Emergent's close partnership with B.C. public health authorities underscores the company's commitment to addressing public health crises, with plans to continue supporting community health and safety through product innovation and strategic initiatives.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy EBS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on EBS
Wall Street analysts forecast EBS stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 8.810
Low
15.00
Averages
15.00
High
15.00
Current: 8.810
Low
15.00
Averages
15.00
High
15.00
About EBS
Emergent BioSolutions, Inc. is a life sciences company. It is focused on providing preparedness and response solutions addressing accidental, deliberate and naturally occurring public health threats. Its solutions include a product portfolio, a product development portfolio, and a contract development and manufacturing services portfolio. Its segments include Commercial Products, MCM Products, and Services segment. Its Commercial Product segment consists of NARCAN Nasal Spray. Its MCM Products segment consists of Anthrax MCM products, Smallpox MCM products and Other Products. Its Services segment consists of its Bioservices portfolio. NARCAN (naloxone HCl) Nasal Spray, an intranasal formulation of naloxone, is developed for the emergency treatment of known or suspected opioid overdose as manifested by respiratory and central nervous system depression. Its Bioservices consist of development services, bulk drug substance manufacturing, fill, finish, and packaging of final drug products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Emergent Partners with BC Health Authority to Expand NARCAN® Program
- Partnership Expansion: Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program, following an $18 million CAD investment by the B.C. government aimed at enhancing community access to naloxone and addressing the opioid crisis.
- Delivery Milestones: Since 2016, Emergent has delivered over 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., showcasing the company's robust capability in responding to public health threats and solidifying its leadership in life-saving products.
- Community Impact: The expansion will make NARCAN® Nasal Spray available in various communities, pharmacies, and public institutions across B.C., significantly enhancing public response capabilities to opioid overdoses and potentially reducing related mortality rates.
- Strategic Collaboration: Emergent's close partnership with B.C. public health authorities underscores the company's commitment to addressing public health crises, with plans to continue supporting community health and safety through product innovation and strategic initiatives.
See More
Emergent BioSolutions Secures $54M Contract for Smallpox Preparedness
- Contract Award: Emergent BioSolutions announced it has secured a contract valued at approximately $54 million to deliver CNJ-016® to the U.S. Department of Health and Human Services' ASPR, enhancing smallpox preparedness and underscoring the company's critical role in biodefense.
- Incremental Orders: The company has also secured new incremental orders worth $6.6 million with an international government partner for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), which will support the partner's smallpox biodefense strategy, further solidifying Emergent's market position.
- Canadian Agreements: Emergent recently executed multi-year agreements with the Government of Canada valued at up to C$140 million to bolster the country's biologic threat preparedness and response infrastructure, with over C$35 million in orders expected in 2026, showcasing the company's expansion potential in international markets.
- Financial Outlook: Despite facing challenges with weak 2026 revenue guidance, Emergent BioSolutions has set a revenue target of $720 million to $760 million for 2026, indicating that the company is advancing its transformation plan to achieve long-term growth.
See More
Emergent BioSolutions Secures $54 Million Contract for Smallpox Preparedness
- Significant Contract Value: Emergent BioSolutions has secured a contract worth approximately $54 million to deliver CNJ-016® to the ASPR, enhancing U.S. capabilities in treating complications from smallpox vaccination, thereby bolstering national public health security.
- Incremental International Orders: The company has also received new orders valued at $6.6 million from an international government partner for ACAM2000® vaccine, which not only supports the partner's biodefense strategy but also highlights Emergent's importance in global threat preparedness.
- Long-Term Partnerships: Emergent's multi-year agreements with the Government of Canada, valued up to CAD 140 million, with over CAD 35 million in orders expected in 2026, demonstrate the company's strong position and market demand in the biological threat preparedness sector.
- Product Safety Information: Both CNJ-016® and ACAM2000® have FDA-approved indications and important safety information, ensuring effective management of health risks for patients during use, further solidifying Emergent's leadership in the biodefense product market.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
Emergent BioSolutions' 2026 Revenue Guidance Falls Short of Expectations
- Revenue Guidance Miss: Emergent BioSolutions announced a 2026 revenue forecast of $720M to $760M, significantly below the consensus estimate of $1.16B, resulting in a ~23% drop in stock price during Friday morning trading.
- Disappointing Financial Results: The company's Q4 results showed a year-over-year revenue decline of ~24% to $148.7M, with a non-GAAP EPS of -$0.43 compared to $0.05 in the same period last year, indicating a substantial deterioration in profitability.
- Improved Cash Position: By the end of 2025, Emergent reported cash, cash equivalents, and restricted cash of $209.1M, up from $105.6M at the end of 2024, reflecting an improvement in liquidity management despite operational challenges.
- Stock Buyback Program: The company authorized a $50 million stock repurchase program aimed at enhancing shareholder value, demonstrating management's confidence in future growth prospects despite the current financial setbacks.
See More
Emergent Partners with BC Health Authority to Expand NARCAN® Program
- Partnership Expansion: Emergent BioSolutions has partnered with the B.C. Provincial Health Services Authority to supply NARCAN® Nasal Spray for the province's Take-Home Naloxone Program, following an $18 million CAD investment by the B.C. government aimed at enhancing community access to naloxone and addressing the opioid crisis.
- Delivery Milestones: Since 2016, Emergent has delivered over 100 million doses of NARCAN® Nasal Spray across Canada and the U.S., showcasing the company's robust capability in responding to public health threats and solidifying its leadership in life-saving products.
- Community Impact: The expansion will make NARCAN® Nasal Spray available in various communities, pharmacies, and public institutions across B.C., significantly enhancing public response capabilities to opioid overdoses and potentially reducing related mortality rates.
- Strategic Collaboration: Emergent's close partnership with B.C. public health authorities underscores the company's commitment to addressing public health crises, with plans to continue supporting community health and safety through product innovation and strategic initiatives.
See More
Emergent BioSolutions Secures $54M Contract for Smallpox Preparedness
- Contract Award: Emergent BioSolutions announced it has secured a contract valued at approximately $54 million to deliver CNJ-016® to the U.S. Department of Health and Human Services' ASPR, enhancing smallpox preparedness and underscoring the company's critical role in biodefense.
- Incremental Orders: The company has also secured new incremental orders worth $6.6 million with an international government partner for ACAM2000® (Smallpox (Vaccinia) Vaccine, Live), which will support the partner's smallpox biodefense strategy, further solidifying Emergent's market position.
- Canadian Agreements: Emergent recently executed multi-year agreements with the Government of Canada valued at up to C$140 million to bolster the country's biologic threat preparedness and response infrastructure, with over C$35 million in orders expected in 2026, showcasing the company's expansion potential in international markets.
- Financial Outlook: Despite facing challenges with weak 2026 revenue guidance, Emergent BioSolutions has set a revenue target of $720 million to $760 million for 2026, indicating that the company is advancing its transformation plan to achieve long-term growth.
See More
Emergent BioSolutions Secures $54 Million Contract for Smallpox Preparedness
- Significant Contract Value: Emergent BioSolutions has secured a contract worth approximately $54 million to deliver CNJ-016® to the ASPR, enhancing U.S. capabilities in treating complications from smallpox vaccination, thereby bolstering national public health security.
- Incremental International Orders: The company has also received new orders valued at $6.6 million from an international government partner for ACAM2000® vaccine, which not only supports the partner's biodefense strategy but also highlights Emergent's importance in global threat preparedness.
- Long-Term Partnerships: Emergent's multi-year agreements with the Government of Canada, valued up to CAD 140 million, with over CAD 35 million in orders expected in 2026, demonstrate the company's strong position and market demand in the biological threat preparedness sector.
- Product Safety Information: Both CNJ-016® and ACAM2000® have FDA-approved indications and important safety information, ensuring effective management of health risks for patients during use, further solidifying Emergent's leadership in the biodefense product market.
See More
Flutter Entertainment Reports Disappointing Q4 Results, Shares Plunge
- Disappointing Financial Results: Flutter Entertainment reported Q4 revenue of $4.74 billion, a 25% year-over-year increase, yet it fell short of the market expectation of $4.97 billion, indicating challenges in revenue growth that could impact investor confidence moving forward.
- Earnings Miss: The company posted earnings per share of $1.74, missing the consensus estimate of $1.99, reflecting pressures from rising costs and intensified market competition, which may raise concerns about future profitability among investors.
- Significant Stock Decline: In pre-market trading, Flutter's shares plummeted by 14.8% to $104.84, indicating a strong market reaction to the disappointing earnings report, which could adversely affect the company's short-term market performance.
- Uncertain Future Guidance: Flutter issued weak FY26 revenue guidance in its report, potentially diminishing market confidence in the company's growth prospects and exacerbating stock volatility risks.
See More
U.S. Stocks Decline Midway; Dell Shares Surge Over 21%
- Market Performance: U.S. stocks traded lower midway through the session, with the Nasdaq Composite falling over 1%, the Dow down 1.40% to 48,807.06, and the S&P 500 dropping 0.74% to 6,858.05, indicating overall market weakness.
- Dell's Earnings Beat: Dell Technologies Inc. (NYSE:DELL) shares surged over 21% on Friday after reporting fourth-quarter earnings of $3.89 per share, exceeding the consensus estimate of $3.53, with quarterly revenue hitting $33.38 billion, up from $23.93 billion a year ago, showcasing strong financial performance.
- Sector Dynamics: Consumer staples stocks rose by 1.3%, while financial stocks fell by 2.6%, reflecting mixed reactions across sectors that could influence investors' asset allocation strategies.
- Commodity Market Fluctuations: Oil prices increased by 2% to $66.54, gold rose by 1.1% to $5,252.30, and silver jumped 7.7% to $94.360, indicating active commodity markets and heightened demand for safe-haven assets.
See More
Emergent BioSolutions' 2026 Revenue Guidance Falls Short of Expectations
- Revenue Guidance Miss: Emergent BioSolutions announced a 2026 revenue forecast of $720M to $760M, significantly below the consensus estimate of $1.16B, resulting in a ~23% drop in stock price during Friday morning trading.
- Disappointing Financial Results: The company's Q4 results showed a year-over-year revenue decline of ~24% to $148.7M, with a non-GAAP EPS of -$0.43 compared to $0.05 in the same period last year, indicating a substantial deterioration in profitability.
- Improved Cash Position: By the end of 2025, Emergent reported cash, cash equivalents, and restricted cash of $209.1M, up from $105.6M at the end of 2024, reflecting an improvement in liquidity management despite operational challenges.
- Stock Buyback Program: The company authorized a $50 million stock repurchase program aimed at enhancing shareholder value, demonstrating management's confidence in future growth prospects despite the current financial setbacks.
See More
